Akero Therapeutics (NASDAQ: AKRO) Falls 48% Following 6-Week Analysis of 96-Week Phase 2b SYMMETRY Study for NASH22% (28mg EFX) and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Hot FDA News Momentum Movers

JPMorgan Removes Akero Therapeutics (AKRO) from Analyst Focus List and Catalyst Watch, PT $62October 10, 2023 12:35 PM Akero Therapeutics (AKRO) declines after efruxifermin NASH trial readout disappoints; Is it time to buy?October 10, 2023 8:26 AM Canaccord on Akero Therapeutics (AKRO): 'We would be strong buyers on this weakness'October 10, 2023 8:21 AM Cantor Fitzgerald on Akero Therapeutics (AKRO), 'we expect the stock to trade down'October 10, 2023 7:55 AM 89bio Inc. (ETNB) Trades Lower in Sympathy with Akero Therapeutics (AKRO)October 10, 2023 7:17 AM Akero Therapeutics (AKRO) Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY StudyOctober 10, 2023 7:00 AM Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of LOctober 10, 2023 7:00 AM